Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-8080 vs fulvestrant combined with dalpiciclib in endocrine-resistant advanced or metastatic breast cancer
CTR20260083Phase 3Active
- Sponsor
- Shandong Sende
- Start
- May 2026
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-8080 in breast cancer, sponsored by Shandong Sende. Started May 2026; status: active.
02
Drugs
HRS-8080
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20260083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260083.